Pharmaceutical firm acquires over two acres of land to build new Birmingham HQ

Sterling Pharmaceuticals, a fast-growing pharmaceutical manufacturing company based in Birmingham, has made a remarkable stride in its expansion efforts with the acquisition of over two acres of land.

The land will be used to build 50,000 square foot R&D laboratory, manufacturing facility, warehouse and 4 storey office space in Longbridge, Birmingham.

This strategic move marks a pivotal moment in the company’s evolution, concretising its commitment to growth and innovation within the pharmaceutical industry.

The newly acquired land will be utilised for the construction of Sterling Pharmaceuticals’ state-of-the-art headquarters.

The expansive facility spanning over two acres of land will provide the company with ample space to centralise its scientific and commercial operations including research & development, contract manufacturing and administrative offices in order to widen the scope of its extant excellent service provision to all its customers both within the UK and overseas.

The construction project is estimated to be completed by December 2025.

Sterling Pharmaceuticals is an innovative Contract Research, Development and Manufacturing Organisation (CRDMO) which specialises in the development and large-batch production of non-sterile oral liquids as well as solid dosage forms such as capsules and tablets.

The company also manufactures bespoke ‘unlicensed’ medicines to cater for patients whose medical needs were unmet by licensed medications in the UK through its ‘Sterling Specials’ brand.                                                                                                        

Dr Qamar Nawaz, CEO of Sterling Pharmaceuticals said: “The newly acquired land in Longbridge will support the next exciting phase of growth for our family business. The new space will enable us to take on a significant number of new extra staff, bringing our workforce to around 150 – nearly all in highly skilled jobs”.

Amar Nawaz, Sterling Pharmaceuticals’ director of PharmacoVigilance said: “Acquiring land in the brand-new Business Park at Longbridge, Birmingham is truly significant as the proposed high-specification facility will further enhance the resource configuration of Sterling Pharmaceuticals, bolstering our capacity to support our global network of customers in seamlessly fulfilling their orders whilst improving the health outcomes for patients.  

Sola Adeosun, chief operating officer of Sterling Pharmaceuticals said: “As an ardent part of the Midlands Engine, securing this parcel of land in Longbridge area of Birmingham has been a truly remarkable experience and it is indicative of Sterling Pharmaceuticals’ commitment to its employees, customers, patients, the city of Birmingham and other stakeholders on a global scale.

“This significant acquisition is a remarkable step in fulfilling our mission to enhance the global supply chain through total commitment to product quality, manufacturing excellence and customer satisfaction”.